Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients

References

• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. WHO Library Cataloguing-in-Publication Data; 2016. Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/
   Google Scholar
• Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. Jama. 2016;316:191–210.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2018 Aug 03]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–822.
   PubMed Web of Science ®Google Scholar
• Fisher M, McDonald C, Moyle G, et al. Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor. J Int AIDS Soc. 2014;17:19824.
   PubMed Web of Science ®Google Scholar
• Grant PMCA. Tenofovir and bone health. Curr Opin HIV AIDS. 2016;11:326–332.
   PubMed Web of Science ®Google Scholar
• Pedrol E, Caro-Murillo AM, Castaño MA, et al. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: the TRIP study. HIV Clin Trials. 2015;16:43–48.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Boyd MA. Antiretroviral regimens sparing agents from the nucleoside (tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Res Ther. 2013;10:33.
   PubMed Web of Science ®Google Scholar
• Achhra AC, Mwasakifwa G, Amin JBM. Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Lancet HIV. 2016;3:351–360.
   PubMed Web of Science ®Google Scholar
• Soriano V, Benitez-Gutierrez L, Mendoza C, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017;16:923–932.
   PubMed Web of Science ®Google Scholar
• Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017;239:1–9.
   PubMed Web of Science ®Google Scholar
• Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmgenomics Pers Med. 2012;5:1–17.
   PubMedGoogle Scholar
• Collins F, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–795.
   PubMed Web of Science ®Google Scholar
• Restelli U, Fabbiani M, Di Giambenedetto S, et al. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. Clin Outcomes Res. 2017;9:173–179.
   PubMed Web of Science ®Google Scholar
• Antinori A, Di Biagio A, Marcotullio S, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017;40:86–98.
   Google Scholar
• Juluca [package insert]. USA: ViiV Healthcare; 2017.
   Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–1951.
   PubMed Web of Science ®Google Scholar
• Winston A, Stöhr W, Antinori A, et al. Changes in cognitive function over 96 weeks in naive patients randomized to darunavir-ritonavir plus either raltegravir or tenofovir-emtricitabine: a substudy of the NEAT001/ANRS143 Trial. J Acquir Immune Defic Syndr. 2017;74:185–192.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Le Fevre E, Carr A, et al. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. Aids. 2016;30:1229–1238.
   PubMed Web of Science ®Google Scholar
• Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14:572–580.
   PubMed Web of Science ®Google Scholar
• Cahn P on behalf of the GARDEL Study Group. Durability of dual therapy (DT) with lopinavir/ritonavir (LPV/r) and lamivudine (3TC) in comparison to standard triple drug therapy (TT): 96-week results of the GARDEL study. Abstract PS10/4.15th European AIDS Conference; 2015 Oct 21–24; Barcelona, Spain.
   Google Scholar
• Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the PROGRESS study, 48-week results. HIV Clin Trials. 2011;12:255–267.
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–265.
   PubMed Web of Science ®Google Scholar
• Sued O, Figueroa MI, Gun A et al. Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study. 9th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 2017 July 23-26; Paris, France.
   Google Scholar
• Kozal MJ, Lupo S, De Jesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study result. HIV Clin Trials. 2012;13:119–130.
   PubMed Web of Science ®Google Scholar
• Nozza S, Galli L, Antinori A, et al. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. Clin Microbiol Infect. 2015;21:510.e1-510.e9.
   Google Scholar
• Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PLoS One. 2014;9:1–10.
   Web of Science ®Google Scholar
• An efficacy, safety, and tolerability study comparing dolutegravir plus lamivudine with dolutegravir plus tenofovir/emtricitabine in treatment naïve HIV infected subjects (GEMINI 1). ClinicalTrials.gov Identifier: NCT02831673.
   Google Scholar
• An efficacy, safety, and tolerability study comparing dolutegravir (DTG) plus lamivudine (3TC) with dolutegravir plus tenofovir/emtricitabine in treatment naïve HIV infected subjects (GEMINI 2). ClinicalTrials.gov Identifier: NCT02831764.
   Google Scholar
• Cahn P, Rolón MJ, Figueroa MI, et al. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20:1–7.
   Web of Science ®Google Scholar
• Taiwo BO, Zheng L, Nyaku AN, et al. ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL. 9th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 2017 July 23-26; Paris France.
   Google Scholar
• Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Aids. 2011;25:2113–2122.
   PubMed Web of Science ®Google Scholar
• Li JZ, Chapman B, Charlebois P, et al. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 2014;9:e90485.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hung C-C, Brinson C, et al. Phase III SWORD 1 & 2: switch to DTG + RPV maintains virologic suppression thorugh 48 wks. O-4 Abstract 44LB, 24th Conference on Retroviruses and Opportunistic Infections (CROI); 2017 Febr 13-16; Seattle, US.
   Google Scholar
• Pett SL, Amin J, Horban A, et al. Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first nucleoside/nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: week 48 results of the randomize, multicenter MARCH study. Clin Infect Dis. 2016;63:122–132.
   PubMed Web of Science ®Google Scholar
• Pett SL, Amin J, Horban A, et al. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Med. 2017;130:1–7.
   Google Scholar
• Rossetti B, Gagliardini R, Meini G, et al. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017 Nov 21;12(11):e0187393.
   PubMed Web of Science ®Google Scholar
• Rossetti B, Gagliardini R, Lisi L et al. Drug concentrations, adherence, patient-reported symptoms and health-related quality of life in HIV-infected, virologically controlled patients switching to maraviroc+darunavir/ritonavir or continuing the previous triple therapy: sub-studies from the randomized GUSTA trial. P105, International Congress on HIV Drug Therapy; 2016 Oct 23-26; Glasgow, UK.
   Google Scholar
• Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145–1155.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink H, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:775–784.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017;72:1163–1171.
   PubMed Web of Science ®Google Scholar
• Gagliardini R, Fabbiani M, Quiros Roldan E, et al. Simplification to atazanavir/ritonavir lamivudine versus maintaining atazanavir/ritonavir 2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial. O121, International Congress on HIV Drug Therapy; 2016 Oct 23-26; Glasgow, UK.
   Google Scholar
• Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017;4:e384–e392.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:785–792.
   PubMed Web of Science ®Google Scholar
• Pulido F, Ribera E, Lagarde M et al. Non-inferiority of dual therapy (DT) with darunavir/ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial. O331, International Congress on HIV Drug Therapy; 2016 Oct 23-26; Glasgow, UK.
   Google Scholar
• van Lunzen J, Pozniak A, Gatell JM, et al. Brief report: switch to ritonavir-boosted atazanavir plus raltegravir in virologically suppressed patients with HIV-1 infection: a randomized pilot study. J Acquir Immune Defic Syndr. 2016;71:538–543.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Di Filippo E, Valenti D, et al. NRTI sparing therapy in virologically controlled HIV-1 infected subjects. Results of a controlled, randomized trial (PROBE). J Acquir Immune Defic Syndr. 2016;72:46–51.
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Shimbo T, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013;8:e73639.
   PubMed Web of Science ®Google Scholar
• Joly V, Burdet C Landman R, et al. Promising results of dolutegravir + lamivudine maintenance in ANRS 167 LAMIDOL trial. P-12 Abstract 458, 24th Conference on Retroviruses and Opportunistic Infections (CROI); 2017 Feb 13-16; Seattle, US.
   Google Scholar
• Casado JL, Bañón S, Moreno A, et al. Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients. J Int AIDS Soc. 2014;17:19801.
   PubMed Web of Science ®Google Scholar
• Soulié C, Assoumou L, Darty M, et al. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). J Antimicrob Chemother. 2015;70:3339–3344.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Poli A, et al. Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. J Infect. 2016;73:619–623.
   PubMed Web of Science ®Google Scholar
• Gantner P, Cuzin L, Allavena C, et al. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017;18:704–708.
   PubMed Web of Science ®Google Scholar
• Salter ML, Lau B, Go VF, et al. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis. 2011;53:1256–1264.
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013;207:1359–1369.
   PubMed Web of Science ®Google Scholar
• Dazo C, Fahey P, Puls R, et al. Small but significant and nonprogressive decline in GFR observed in therapy-naïve HIV+ subjects commencing r/ATV, compared to either EFV or ZDV/ABC with TDF/FTC after 48 weeks: a randomized controlled study. 18th Conference on Retroviruses and Opportunistic Infections (CROI); 2011 Febr-March 27-2; Boston, MA.
   Google Scholar
• Post FA. Managing chronic kidney disease in the older adults living with HIV. Curr Opin Infect Dis. 2017;30:4–11.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. Aids. 2006;20:2165–2174.
   PubMed Web of Science ®Google Scholar
• Carr A, Grund B, Neuhaus J, et al. Prevalence and risk factors for low bone mineral density in untreated HIV infection. a substudy of the INSIGHT strategic timimg of antiretroviral treatment trial. HIV Med. 2016;16:137–146.
   Web of Science ®Google Scholar
• Klassen KM, Kimlin MG, Fairley CK, et al. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporos Int. 2016;27:1737–1745.
   PubMed Web of Science ®Google Scholar
• D’Avino A, De Luca A, Lassandro AP, et al. Bone-mineral density after switching to ATV/r+3TC: a substudy of the AtLaS-M trial. Abstract 697, 23th Conference on Retroviruses and Opportunistic Infections (CROI); 2016 Feb 22–25; Boston, MA.
   Google Scholar
• Perez-Molina JA, Rubio R, Rivero A, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother. 2017;72:246–253.
   PubMed Web of Science ®Google Scholar
• McComsey G, Gonzalez-Garcia J, Lupo S, et al. Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF containing regimen to DTG+RPV improves bone mineral density and bone turnover markers over 48 weeks. 9th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 2017 July 23-26;Paris, France.
   Google Scholar
• Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193.
   PubMed Web of Science ®Google Scholar
• Postorino MC, Quiros-Roldan E, Maggiolo F, et al. Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine atazanavir/ritonavir (ATV/r) to abacavir/lamivudine ATV/r in patients with preserved renal function. Open AIDS J. 2016;10:136–143.
   PubMedGoogle Scholar
• Cahn P, Villanueva JA, Arribas J, et al. Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study. J Int AIDS Soc. 2014;17:19554.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Colafigli M, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase+inhibitors atazanavir/ritonavir with virological suppression (atazanavir and lamivudine for treatment simplification, ATLAS pilot study). J Antimicrob Chemother. 2013;68:1364–1372.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Fabbiani M, et al. Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the ATLAS pilot study. J Antimicrob Chemother. 2016;71:3621–3622.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Quiros-Roldan E, et al. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized ATLAS-M trial. J Antimicrob Chemother. 2017;72:2055–2059.
   PubMed Web of Science ®Google Scholar
• The efficacy and safety of dolutegravir-based dual therapies in hiv-infected patients with intolerance or Toxicity to Nucleoside Analogues (TANGO) ClinicalTrials.gov Identifier: NCT02491242.
   Google Scholar
• Price H, Dunn D, Pillay D, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One. 2013;8:1–9.
   Web of Science ®Google Scholar
• Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol. 2017 Nov;11(11):999–1008.
   PubMed Web of Science ®Google Scholar
• Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016 Mar 15;62(6):784–791.
   PubMed Web of Science ®Google Scholar